RxDoctor Payments DataLook up a doctor →

Kevin Dunsmoor, DO

Internal Medicine · Las Vegas, NVNPI 1992963664

Payments from drug & device makers

$241,375in general payments, 2019–2025

Across 895 payments — averaging $269.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$229K
  • AbbVie$2K
  • Novo Nordisk$2K
  • GSK$925
  • AstraZeneca$765
  • Pfizer$750
  • plus $6K from 45 others

What the payments were for

  • Consulting fees$229,10395%
  • Travel & lodging$1400%
  • Food & beverage$12,0325%
  • Education$1000%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$241,375 in reported general payments places this provider in the 95th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$468,436
Medicare patients
991
Services billed
6,292

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide107$108,027
MounjaroTirzepatide96$103,322
JardianceEmpagliflozin68$65,241
EliquisApixaban59$64,558
RybelsusSemaglutide36$41,763
FarxigaDapagliflozin Propanediol59$41,230
TrulicityDulaglutide28$38,398
MyrbetriqMirabegron36$34,112
Synjardy XrEmpagliflozin/Metformin Hcl36$29,363
SynjardyEmpagliflozin/Metformin Hcl17$25,300
VascepaIcosapent Ethyl21$15,600
JanuviaSitagliptin Phosphate17$14,887
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$13,697
XareltoRivaroxaban12$13,579
Tresiba Flextouch U-200Insulin Degludec15$9,813

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,532$149,790143 claims
Lilly USA, LLCMounjaro, Trulicity$458$141,720124 claims
Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Spiriva Respimat$395$126,786134 claims
PfizerEliquis$750$64,55859 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$765$57,94686 claims
Astellas Pharma US IncMyrbetriq$627$34,11236 claims
MerckJanuvia$147$14,88717 claims
Johnson & JohnsonXarelto$602$13,57912 claims
AbbVieSynthroid, Armour Thyroid$2,148$4,60163 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →